FACTS ABOUT MRTX1133 RESISTANCE REVEALED

The identification of KRASG12C inhibitors has reignited fascination in targeting RAS proteins. This function describes the invention in the KRASG12D-specific inhibitor MRTX1133 and demonstrates the feasibility of potently and selectively focusing on this oncogenic variant.One more prospective advantage of combining KRAS inhibitors and checkpoint in